Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2010

View Archived Issues

Clinical and preclinical data suggest potential of teneligliptin in diabetes

Elan Pharma reports effects of ELND-006 on Abeta in animals

Encouraging data disclosed on antidiabetes candidate TAK-875

Biolipox claims new LTC4 synthase inhibitors

Korean scientists disclose new inhibitors of Abeta neurotoxicity

Merck & Co. describes novel GPR109B receptor agonists

Novel HIF-1-alpha activators identified by sanofi-aventis

ABT-288 improves cognition in vivo

SAM-760 under clinical evaluation for treatment of AD

Clinical data on inhaled Technosphere insulin disclosed at ADA

FDA approves Lorus Therapeutics' IND for anticancer agent LOR-253

Watson Pharma licenses Itero's rFSH for female infertility

Health Canada clears phase III ReoT3D trial in head and neck cancer

Almirall presents novel S1P1 receptor agonists

Jevtana launched in U.S. for metastatic hormone-refractory prostate cancer

FDA approves Veltin gel for acne vulgaris in patients age 12 years and older

Takeda's Lampion pack approved in Japan

Geron begins phase II imetelstat trial in advanced non-small cell lung cancer

Phase II trial of interferon alfa-n3 for flu cleared in India

FDA begins NDA review for new oral rufinamide formulation

Tenofovir vaginal gel progresses in clinical trials for HIV prevention

Pfizer suspends tanezumab trials in chronic pain at request of FDA

Actelion's option to acquire Trophos depends on phase III olesoxime data

FLAP inhibitors enter phase II studies in asthma

Pharming finalizes divestment of DNage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...